Review Article
Genomic Medicine
Alan E. Guttmacher, M.D., Editor, Francis S. Collins, M.D., Ph.D., Editor
Population Screening in the Age of Genomic Medicine
N Engl J Med 2003; 348:50-58January 2, 2003
- Article
Physicians in the era of genomic medicine will have the opportunity to move from intense, crisis-driven intervention to predictive medicine. Over the next decade or two, it seems likely that we will screen entire populations or specific subgroups for genetic information in order to target interventions to individual patients that will improve their health and prevent disease. Until now, population screening involving genetics has focused on the identification of persons with certain mendelian disorders before the appearance of symptoms and thus on the prevention of illness1 (e.g., screening of newborns for phenylketonuria), the testing of selected populations for carrier status, and the use of prenatal diagnosis to reduce the frequency of disease in subsequent generations (e.g., screening to identify carriers of Tay–Sachs disease among Ashkenazi Jews). But in the future, genetic information will increasingly be used in population screening to determine individual susceptibility to common disorders such as heart disease, diabetes, and cancer. Such screening will identify groups at risk so that primary-prevention efforts (e.g., diet and exercise) or secondary-prevention efforts (early detection or pharmacologic intervention) can be initiated. Such information could lead to the modification of screening recommendations, which are currently based on population averages (e.g., screening of people over 50 years of age for the early detection of colorectal cancer).2
In this review, we describe current and evolving principles of population screening in genetics. We also provide examples of issues related to screening in the era of genomic medicine.
Principles of Population Screening
The principles of population screening developed in 1968 by Wilson and Jungner3 form a basis for applying genetics in population screening. These principles emphasize the importance of a given condition to public health, the availability of an effective screening test, the availability of treatment to prevent disease during a latent period, and cost considerations. Wald outlined three elements of screening: the identification of persons likely to be at high risk for a specific disorder so that further testing can be done and preventive actions taken, outreach to populations that have not sought medical attention for the condition, and follow-up and intervention to benefit the screened persons.4 Several groups have used these principles to develop policies regarding genetic testing in populations.5 Screening of newborns, which has been carried out in the United States since the early 1960s, serves as a foundation for other types of genetic screening.6,7
Newborn Screening
Each state (and the District of Columbia) determines its own list of diseases and methods for the screening of newborns. Only phenylketonuria and hypothyroidism are screened for by all these jurisdictions.7 Table 1Table 1
Disorders Included in Newborn-Screening Programs. lists the disorders that are included in many state programs for newborn screening and gives one an idea of the diversity of techniques employed. The addition of a test or a method to a state's screening program depends on the efforts of advisory boards for newborn screening, political lobbying of legislatures, and the efforts of laboratory personnel for newborn screening. There has often been a lack of research to demonstrate the effectiveness of screening and treatment for a disorder, either before or after the disease is added to the newborn-screening program. The technological spectrum ranges from the original Guthrie bacterial inhibition assay, developed in the late 1950s,8 to tandem mass spectrometry9,10 and DNA analysis.11-13 With the use of DNA testing of the blood blot obtained from the screening of a newborn, the state of Texas reduced the age at confirmation of the diagnosis of sickle cell disease from four months to two months.14 Rapid diagnostic confirmation is imperative for the initiation of penicillin prophylaxis to prevent illness and death in patients with sickle cell disease.15,16 The cost of this follow-up test is $10 or less for each positive sample from the original screening.14 Two-tiered testing is also used for congenital hypothyroidism, since patients with primary hypothyroidism have elevated levels of thyrotropin and low levels of thyroxine.17,18 The two-tiered strategy provides better sensitivity and specificity than either test alone. However, the health care professional needs to use clinical judgment in addition to the results of newborn screening. If a patient with a negative newborn-screening test has symptoms of congenital hypothyroidism, clinical acumen should override the test result and specific diagnostic testing should be performed.17 The results of screening tests are not infallible because of the possibility of biologic, clerical, and laboratory errors.19-21
Audiometry is used to screen newborns for hearing defects. The frequency of deafness in childhood is as high as 1 in 500.22 These programs are based in hospitals and are therefore decentralized.7 Mutations in the gene for connexin 26 account for 40 percent of all cases of childhood hearing loss, with a carrier rate of 3 percent in the population.23 A single mutation is responsible for most of these cases in a mixed U.S. population.23 A different mutation is predominant among Ashkenazi Jews.24 Two-tiered testing in which audiometry is followed by DNA testing for mutations in the connexin 26 gene may be a useful and cost-effective approach to screening for hearing loss.25 Early detection provides the possibility of aggressive intervention to improve a child's language skills, provide cochlear implants, or do both.23
In 1999, the American Academy of Pediatrics and the Health Resources and Services Administration convened the Newborn Screening Task Force to address the lack of consistency in the disorders included in screening programs and the testing methods used in the various states.26 The group concluded that there should be a national consensus on the diseases tested for in state programs of newborn screening. The American Academy of Pediatrics, American College of Medical Genetics, Health Resources and Services Administration, Centers for Disease Control and Prevention, March of Dimes, and other groups are working together to create a national agenda for newborn screening.
A disorder that may be included in newborn screening tests is cystic fibrosis. Cystic fibrosis has been included in the newborn-screening program in Colorado since the demonstration that some affected infants had malnutrition as a result of the pancreatic dysfunction.27 This observation was confirmed by a randomized trial in Wisconsin involving infants with a positive newborn-screening test for cystic fibrosis.28 In the study, infants with a positive test were randomly assigned to a screened group (in which physicians were informed of the positive screening result) or a control group (in which physicians were informed of the positive screening result when the child was four years of age if cystic fibrosis had not been diagnosed clinically or if the child's parents had not asked about the results of the screening test). In Wisconsin, infants are first tested with the use of an immunoreactive trypsinogen assay29; if the result is positive, the test is followed up with a DNA test of the original specimen of dried blood obtained for newborn screening.30-32 The cost of each follow-up DNA test for infants with positive results on the immunoreactive trypsinogen assay was estimated to be $3 to $5.31
A new form of technology, tandem mass spectrometry, detects more than 20 disorders, not all of which can be treated. A justification for introducing tandem mass spectrometry is the identification of newborns with medium-chain acyl–coenzyme A (CoA) dehydrogenase deficiency (Figure 1Figure 1
Results of Screening by Tandem Mass Spectrometry for Medium-Chain Acyl–Coenzyme A (CoA) Dehydrogenase Deficiency in an Affected Patient (Panel A) and a Control Subject (Panel B).). Without early detection and intervention, this deficiency leads to episodic hypoglycemia, seizures, coma associated with intercurrent illnesses and fasting, and a risk of death of approximately 20 percent after the first episode in the first and second year of life.33,34 Management of medium-chain acyl–CoA dehydrogenase deficiency involves educating families about the dangers of hypoglycemia, which can be triggered by fasting, with resulting fat catabolism, during intercurrent illnesses and by inadequate caloric intake, and of the need for aggressive intervention with intravenous glucose if hypoglycemia does occur. For many of the other disorders detected by tandem mass spectrometry, treatment is not available, but families will potentially be spared “diagnostic odysseys” with a severely ill child.35 The eventual goal is collaborative research to determine the appropriate treatment after early diagnosis.7,36 In addition, this information may be useful for genetic counseling of these families. A cause for concern is that tandem mass spectrometry may detect metabolic variations of unknown clinical significance, creating unwarranted anxiety in parents and health care professionals.Carrier Screening of Adult Populations for Single-Gene Disorders
Tay–Sachs Disease
Carrier screening for Tay–Sachs disease has targeted Ashkenazi Jewish populations of childbearing age.37 In a 30-year period, 51,000 carriers have been identified, resulting in the identification of 1400 two-carrier couples.37 Another approach has been taken in Montreal, where high-school students learn about Tay–Sachs disease and thalassemia as part of a biology course. Those of Ashkenazi Jewish descent can request carrier testing for Tay–Sachs disease, and those of Mediterranean ancestry can be tested for thalassemia.38 When women who have been identified as carriers in high school later consider becoming pregnant, they bring their partners in for testing. Although this program has been very successful in Canada, the culture and the legal environment in the United States, including a standard that does not allow high-school students to consent to medical care and the implications for insurability, may prohibit the adoption of such a model.39
Cystic Fibrosis
Northern Europeans have a carrier frequency of cystic fibrosis of 1 in 25 to 1 in 30; the rate is lower in other ethnic and cultural groups.17 A 1997 National Institutes of Health Consensus Development Conference40 recommended that the following populations be screened for mutations associated with cystic fibrosis: the adult family members of patients with cystic fibrosis, the partners of patients with cystic fibrosis, couples planning a pregnancy, and couples seeking prenatal care. Since more than 900 different mutations associated with cystic fibrosis have been reported in the literature,41 the establishment of screening programs has been difficult. However, the American College of Medical Genetics, the American College of Obstetricians and Gynecologists, and the National Institutes of Health agreed that mutations with a carrier frequency of at least 0.1 percent in the general population should be screened for, resulting in a panel of 25 mutations recommended for carrier testing.42 These guidelines suggest that carrier testing should be offered to all non-Jewish white persons and Ashkenazi Jews and that other ethnic and cultural groups should be informed of the limitations of the panel to detect carriers in their group (in the case of black persons) or of the low incidence of cystic fibrosis in their group (in the cases of Asian and Native American persons).
Mutations in the gene associated with cystic fibrosis have also been associated with obstructive azoospermia in men43 and with chronic rhinosinusitis.44,45 The guidelines recommend including in the screening panel a test for the R117H mutation, which is associated with congenital bilateral absence of the vas deferens.42 If the R117H mutation is found, further testing and genetic counseling are recommended.42
Population Screening for Genetic Susceptibility to Common Diseases
Several groups have recently addressed the value of population screening for genetic susceptibility to conditions with onset in adulthood.46-48 Table 2Table 2
Principles of Population Screening as Applied to Genetic Susceptibility to Disease. presents a synthesis of the suggested modifications to the 1968 criteria,3 based on current principles.Hereditary hemochromatosis and the thrombophilia that results from carrying a single copy of a factor V Leiden gene are two adult-onset illnesses to which the suggested revised principles for population screening would apply (Table 2), and these illnesses also reflect the complex scientific and social issues involved in screening for risk factors for disease. As shown by Wald et al.,49 screening for risk factors for nondiscrete traits that are distributed continuously may not be beneficial even if the factors are associated with a high risk of disease (e.g., high cholesterol levels and heart disease). This is because risk factors are determined by comparing the probability of disease at each end of the distribution of the risk factor (those with the highest level of risk and those with the lowest level of risk). Those with a moderate level of risk are not considered. The likelihood of a disorder, given a positive screening result, is expressed relative to the average risk of the entire population. The goal of screening is to identify individual persons with a high risk in comparison to everyone else.
Hereditary Hemochromatosis
Many consider hereditary hemochromatosis to be the key example of the need for population screening in the genomic era,50 but gaps in our knowledge preclude the recommendation of population screening for this disorder. This policy issue was discussed by an expert-panel workshop held by the Centers for Disease Control and Prevention and the National Human Genome Research Institute.51 The panel concluded that population genetic testing for mutations in HFE, the gene for hereditary hemochromatosis, could not be recommended because of uncertainty about the natural history of the disease, age-related penetrance, optimal care for persons without symptoms who are found to carry mutations, and the psychosocial impact of genetic testing.52,53 On the other hand, mutation analysis may be useful in confirming the diagnosis of hereditary hemochromatosis in persons with abnormal indexes of iron metabolism. A meta-analysis of studies54 showed that homozygosity for the C282Y mutation was associated with the highest risk of hereditary hemochromatosis. The risks associated with other genotypes, including C282Y/H63D and H63D/H63D, were much lower. A recent large cohort study in the Kaiser Permanente Southern California health care network suggests that the disease penetrance for HFE mutations may be quite low.55 Only 1 of the 152 subjects who were homozygous for C282Y had symptoms of hereditary hemochromatosis.
Several questions remain regarding the benefits and risks of identifying and treating persons without symptoms who are at high risk for hereditary hemochromatosis (i.e., through population screening). This process should be clearly distinguished from early case finding, which could include testing of iron status, and analysis for mutations in HFE, in persons who present with clinical symptoms consistent with a diagnosis of hereditary hemochromatosis. The natural history of hereditary hemochromatosis — particularly age-related penetrance — remains unknown. Despite the relatively high prevalence of the two most common mutations in the U.S. population,56 questions persist regarding the nature and prevalence of mutations in specific ethnic and cultural groups, as well as the morbidity57 and mortality58 associated with this disease. Therefore, questions remain concerning the persons most likely to benefit from early treatment and thus about the optimal timing of screening and effective intervention, as well as ethical and psychosocial issues59 (Table 2).
Factor V Leiden
Factor V is an important component of the coagulation cascade leading to the conversion of prothrombin into thrombin and the formation of clots.60 In factor V Leiden, the triplet coding for arginine (CGA) at codon 506 is replaced by CAA, which codes for glutamine (R506Q), resulting in thrombophilia or an increased propensity for clot formation.61 The prevalence of factor V Leiden varies.62,63 Among persons of northern European descent, the prevalence is about 5 percent. The highest prevalence of factor V Leiden is found in Sweden and in some Middle Eastern countries; it is virtually absent in African and Asian populations. Heterozygosity for factor V Leiden results in an increase in the incidence of venous thrombosis by a factor of 4 to 9.64,65
An interaction between factor V Leiden and the use of oral contraceptives was originally found in a case–control study of risk factors for venous thrombosis.66 Although the use of oral contraceptives alone increases the risk of venous thrombosis by a factor of about 4 and the presence of factor V Leiden alone increases the risk by a factor of about 7, their joint effect was an increase by a factor of more than 30. In spite of the high relative risk, the absolute risk was relatively low (about 28 per 10,000 person-years) among women with factor V Leiden who used oral contraceptives, because the incidence of this complication is relatively low in the population.
The question of whether it is beneficial to screen women for factor V Leiden before prescribing oral contraceptives remains controversial. Venous thrombosis is relatively rare, and the mortality associated with venous thrombosis is low among young women.67 More than half a million women would need to be screened for factor V Leiden — resulting in tens of thousands of women being denied prescriptions for oral contraceptives — to prevent a single death. In addition to medical and financial considerations, there are issues related to the quality of life, the risk of illness and death from unwanted pregnancy, and concern about possible discrimination by insurance companies. In 2001, the American College of Medical Genetics stated that the opinions and practices regarding testing for factor V Leiden vary considerably, and no consensus has emerged.68
For the individual healthy woman contemplating the use of oral contraceptives, the risk–benefit equation does not currently favor screening. For women without symptoms who have family histories of multiple thrombosis, there are no evidence-based guidelines, and decisions will have to be reached individually, without reliance on population-based recommendations.
These examples show why it is essential that data continue to be analyzed to inform decision making for individual persons and populations.
Ethical, Legal, and Social Issues
The following are among the ethical, legal, and social issues involved in population-based screening that confront health care providers, policymakers, and consumers.
Testing Children for Adult-Onset Disorders
Two committees of the American Academy of Pediatrics have recently addressed the issue of molecular genetic testing of children and adolescents for adult-onset disease.69,70 The Committee on Genetics69 recommended that persons under 18 years of age be tested only if testing offers immediate medical benefits or if another family member benefits and there is no anticipated harm to the person being tested. The committee regarded genetic counseling before and after testing as an essential part of the process.
The Committee on Bioethics70 agreed with the Newborn Screening Task Force27 that the inclusion of tests in the newborn-screening battery should be based on evidence and that there should be informed consent for newborn screening (which is currently not required in the majority of states). The Committee on Bioethics did not support the use of carrier screening in persons under 18 years of age, except in the case of an adolescent who is pregnant or is planning a pregnancy. It recommended against predictive testing for adult-onset disorders in persons under 18 years.
Unanticipated Information
Misattribution of Paternity
The American Society of Human Genetics has recommended that family members not be informed of misattributed paternity unless determination of paternity was the purpose of the test.71 However, it must be recognized that such a policy may lead to misinformation regarding genetic risk.
Unexpected Associations among Diseases
In the course of screening for one disease, information regarding another disease may be discovered. Although the person may have requested screening for the first disorder, the presence of the second disorder may be unanticipated and may lead to stigmatization and discrimination on the part of insurance companies and employers. Informed consent should include cautions regarding unexpected findings from the testing.
Oversight and Policy Issues
In 1999, the Secretary's Advisory Committee on Genetic Testing was established to advise the Department of Health and Human Services on the medical, scientific, ethical, legal, and social issues raised by the development and use of genetic tests (http://www4.od.nih.gov/oba/sacgt.htm).72 The committee conducted public outreach to identify issues regarding genetic testing. There was an overwhelming concern on the part of the public regarding discrimination in employment and insurance. The advisory committee recommended the support of legislation preventing discrimination on the basis of genetic information and increased oversight of genetic testing. The Food and Drug Administration was charged as the lead agency and was urged to take an innovative approach and consult experts outside the agency. The goal is to generate specific language for the labeling of genetic tests, much as drugs are described in the Physicians' Desk Reference.73 Such labeling would provide persons considering, and health professionals recommending, genetic tests with information about the clinical validity and value of the test — what information the test will provide, what choices will be available to people after they know their test results, and the limits of the test.
In conclusion, although the use of genetic information for population screening has great potential, much careful research must be done to ensure that such screening tests, once introduced, will be beneficial and cost effective.
Source Information
From the Office of Genomics and Disease Prevention, Centers for Disease Control and Prevention, Atlanta (M.J.K.); and the Departments of Human Genetics and Pediatrics, the David Geffen School of Medicine at UCLA, and the UCLA Center for Society, the Individual and Genetics, Los Angeles (L.L.M., E.R.B.M.).
Address reprint requests to Dr. Edward McCabe at the Department of Pediatrics, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave., Los Angeles, CA 90095-1752, or at emccabe@mednet.ucla.edu.
- References
References
1
Juengst ET . “Prevention“ and the goals of genetic medicine. Hum Gene Ther 1995;6:1595-1605
CrossRef | Web of Science | Medline2
Ransohoff DF ,Sandler RS . Screening for colorectal cancer. N Engl J Med 2002;346:40-44
Full Text | Web of Science | Medline3
Wilson JMG, Jungner G. Principles and practice of screening for disease. Public health papers no. 34. Geneva: World Health Organization, 1968.
4
Wald NJ . The definition of screening. J Med Screen 2001;8:1-1
CrossRef | Web of Science | Medline5
Wilfond BS, Thomson EJ. Models of public health genetics policy development. In: Khoury MJ, Burke W, Thomson EJ, eds. Genetics and public health in the 21st century: using genetic information to improve health and prevent disease. New York: Oxford University Press, 2000:61-82.
6
Committee for the Study of Inborn Errors of Metabolism. Genetic screening: programs, principles, and research. Washington, D.C.: National Academy of Sciences, 1975.
7
McCabe LL, Therrell BL Jr, McCabe ERB. Newborn screening: rationale for a comprehensive, fully integrated public health system. Mol Genet Metab (in press).
8
Guthrie R ,Susi A . A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-343
Web of Science | Medline9
Chace DH ,Hillman SL ,Van Hove JL ,Naylor EW . Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997;43:2106-2113
Web of Science | Medline10
Andresen BS ,Dobrowolski SF ,O'Reilly L , et al. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 2001;68:1408-1418
CrossRef | Web of Science | Medline11
McCabe ERB ,Huang S-Z ,Seltzer WK ,Law ML . DNA microextraction from dried blood spots on filter paper blotters: potential applications to newborn screening. Hum Genet 1987;75:213-216
CrossRef | Web of Science | Medline12
Jinks DC ,Minter M ,Tarver DA ,Vanderford M ,Hejtmancik JF ,McCabe ERB . Molecular genetic diagnosis of sickle cell disease using dried blood specimens on blotters used for newborn screening. Hum Genet 1989;81:363-366
CrossRef | Web of Science | Medline13
Descartes M ,Huang Y ,Zhang Y-H , et al. Genotypic confirmation from the original dried blood specimens in a neonatal hemoglobinopathy screening program. Pediatr Res 1992;31:217-221
CrossRef | Web of Science | Medline14
Zhang Y-H ,McCabe LL ,Wilborn M ,Therrell BL Jr ,McCabe ERB . Application of molecular genetics in public health: improved follow-up in a neonatal hemoglobinopathy screening program. Biochem Med Metab Biol 1994;52:27-35
CrossRef | Medline15
Gaston MH ,Verter JI ,Woods G , et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med 1986;314:1593-1599
Full Text | Web of Science | Medline16
Consensus Development Panel. Newborn screening for sickle cell disease and other hemoglobinopathies. NIH consensus statement. Vol. 6. No. 9. Bethesda, Md.: NIH Office of Medical Applications of Research, 1987:1-22.
17
American Academy of Pediatrics Committee on Genetics
Web of Science | Medline18
Burrow GN, Dussault JH, eds. Neonatal thyroid screening. New York: Raven Press, 1980:155.
19
McCabe ERB ,McCabe L ,Mosher GA ,Allen RJ ,Berman JL . Newborn screening for phenylketonuria: predictive validity as a function of age. Pediatrics 1983;72:390-398
Web of Science | Medline20
Holtzman C ,Slazyk WE ,Cordero JF ,Hannon WH . Descriptive epidemiology of missed cases of phenylketonuria and congenital hypothyroidism. Pediatrics 1986;78:553-558
Web of Science | Medline21
Dequeker E ,Cassiman J-J . Quality evaluation of data interpretation and reporting. Am J Hum Genet 2001;69:Suppl:438-438 abstract.
Web of Science22
Mehl AL ,Thomson V . The Colorado Newborn Hearing Screening Project, 1992-1999: on the threshold of effective population-based universal newborn hearing screening. Pediatrics 2002;109:134-134 abstract.
CrossRef | Web of Science23
Cohn ES ,Kelley PM . Clinical phenotype and mutations in connexin 26 (DFNB1/GJB2), the most common cause of childhood hearing loss. Am J Med Genet 1999;89:130-136
CrossRef | Web of Science | Medline24
Morrell RJ ,Kim HJ ,Hood LJ , et al. Mutations in the connexin 26 gene (GJB2) among Ashkenazi Jews with nonsyndromic recessive deafness. N Engl J Med 1998;339:1500-1505
Full Text | Web of Science | Medline25
McCabe ERB ,McCabe LL . State-of-the-art for DNA technology in newborn screening. Acta Paediatr Suppl 1999;88:58-60
CrossRef | Medline26
Newborn Screening Task Force
Web of Science | Medline27
Reardon MC ,Hammond KB ,Accurso FJ , et al. Nutritional deficits exist before 2 months of age in some infants with cystic fibrosis identified by screening test. J Pediatr 1984;105:271-274
CrossRef | Web of Science | Medline28
Farrell PM ,Kosorok MR ,Rock MJ , et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics 2001;107:1-13
CrossRef | Web of Science | Medline29
Hassemer DJ ,Laessig RH ,Hoffman GL ,Farrell PM . Laboratory quality control issues related to screening newborns for cystic fibrosis using immunoreactive trypsin. Pediatr Pulmonol Suppl 1991;7:76-83
CrossRef | Medline30
Seltzer WK ,Accurso F ,Fall MZ , et al. Screening for cystic fibrosis: feasibility of molecular genetic analysis of dried blood specimens. Biochem Med Metab Biol 1991;46:105-109
CrossRef | Medline31
Gregg RG ,Wilfond BS ,Farrell PM ,Laxova A ,Hassemer D ,Mischler EH . Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet 1993;52:616-626
Web of Science | Medline32
Kant JA ,Mifflin TE ,McGlennen R ,Rice E ,Naylor E ,Cooper DL . Molecular diagnosis of cystic fibrosis. Clin Lab Med 1995;15:877-898
Web of Science | Medline33
Roe CR, Ding J. Mitochondrial fatty acid oxidation disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic & molecular bases of inherited disease. 8th ed. Vol. 2. New York: McGraw-Hill, 2001:2297-326.
34
Matsubara Y ,Narisawa K ,Tada K , et al. Prevalence of K329E mutation in medium-chain acyl-CoA dehydrogenase gene determined from Guthrie cards. Lancet 1991;338:552-553
CrossRef | Web of Science | Medline35
Wilcken B ,Travert G . Neonatal screening for cystic fibrosis: present and future. Acta Paediatr Suppl 1999;88:33-35
CrossRef | Medline36
Naylor EW ,Chace DH . Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. J Child Neurol 1999;14:Suppl 1:S4-S8
Web of Science | Medline37
Kaback MM . Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur J Pediatr 2000;159:Suppl 3:S192-S195
CrossRef | Web of Science | Medline38
Mitchell JJ ,Capua A ,Clow C ,Scriver CR . Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and β-thalassemia disease carriers in high schools. Am J Hum Genet 1996;59:793-798
Web of Science | Medline39
McCabe L . Efficacy of a targeted genetic screening program for adolescents. Am J Hum Genet 1996;59:762-763
Web of Science | Medline40
Genetic testing for cystic fibrosis: National Institutes of Health Consensus Development Conference statement on genetic testing for cystic fibrosis. Arch Intern Med 1999;159:1529-1539
CrossRef | Web of Science | Medline41
Grody WW ,Desnick RJ . Cystic fibrosis population carrier screening: here at last -- are we ready? Genet Med 2001;3:87-90
CrossRef | Web of Science | Medline42
Grody WW ,Cutting GR ,Klinger KW ,Richards CS ,Watson MS ,Desnick RJ . Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001;3:149-154
CrossRef | Medline43
Mak V ,Zielenski J ,Tsui L-C , et al. Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia. JAMA 1999;281:2217-2224
CrossRef | Web of Science | Medline44
Raman V ,Clary R ,Siegrist KL ,Zehnbauer B ,Chatila TA . Increased prevalence of mutations in the cystic fibrosis transmembrane conductance regulator in children with chronic rhinosinusitis. Pediatrics 2002;109:136-137 abstract.
CrossRef | Web of Science45
Wang XJ ,Moylan B ,Leopold DA , et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 2000;284:1814-1819
CrossRef | Web of Science | Medline46
Goel V . Appraising organised screening programmes for testing for genetic susceptibility to cancer. BMJ 2001;322:1174-1178
CrossRef | Web of Science | Medline47
Khoury MJ, Burke W, Thomson EJ. Genetics and public health: a framework for the integration of human genetics into public health practices. In: Khoury MJ, Burke W, Thomson EJ, eds. Genetics and public health in the 21st century: using genetic information to improve health and prevent disease. New York: Oxford University Press, 2000:3-24.
48
Burke W ,Coughlin SS ,Lee NC ,Weed DL ,Khoury MJ . Application of population screening principles to genetic screening for adult-onset conditions. Genet Test 2001;5:201-211
CrossRef | Web of Science | Medline49
Wald NJ ,Hackshaw AK ,Frost CD . When can a risk factor be used as a worthwhile screening test? BMJ 1999;319:1562-1565
CrossRef | Web of Science | Medline50
Collins FS. Keynote speech at the Second National Conference on Genetics and Public Health, December 1999. Atlanta: Office of Genetics & Disease Prevention, 2000. (Accessed December 6, 2002, at http://www.cdc.gov/genomics/info/conference/intro.htm.)
51
Cogswell ME ,Burke W ,McDonnell SM ,Franks AL . Screening for hemochromatosis: a public health perspective. Am J Prev Med 1999;16:134-140
CrossRef | Web of Science | Medline52
Burke W ,Thomson E ,Khoury MJ , et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 1998;280:172-178
CrossRef | Web of Science | Medline53
EASL International Consensus Conference on Hemochromatosis
CrossRef | Web of Science54
Burke W ,Imperatore G ,McDonnell SM ,Baron RC ,Khoury MJ . Contribution of different HFE genotypes to iron overload disease: a pooled analysis. Genet Med 2000;2:271-277
CrossRef | Web of Science | Medline55
Beutler E ,Felitti VJ ,Koziol JA ,Ho NJ ,Gelbart T . Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-218
CrossRef | Web of Science | Medline56
Steinberg KK ,Cogswell ME ,Chang JC , et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001;285:2216-2222
CrossRef | Web of Science | Medline57
Brown AS ,Gwinn M ,Cogswell ME ,Khoury MJ . Hemochromatosis-associated morbidity in the United States: an analysis of the National Hospital Discharge Survey, 1979-1997. Genet Med 2001;3:109-111
CrossRef | Web of Science | Medline58
Yang Q ,McDonnell SM ,Khoury MJ ,Cono J ,Parrish RG . Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998;129:946-953
Web of Science | Medline59
Imperatore G, Valdez R, Burke W. Case study: hereditary hemochromatosis. In: Khoury MJ, Little J, Burke W, eds. Human genome epidemiology: scientific foundation for using genetic information to improve health and prevent disease. New York: Oxford University Press (in press).
60
Greenberg DL, Davie EW. Introduction to hemostasis and the vitamin K-dependent coagulation factors. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic & molecular bases of inherited disease. 8th ed. Vol. 3. New York: McGraw-Hill, 2001:4293-326.
61
Esmon CT. Anticoagulation protein C/thrombomodulin pathway. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic & molecular bases of inherited disease. 8th ed. Vol. 3. New York: McGraw-Hill, 2001:4327-43.
62
Rees DC ,Cox M ,Clegg JB . World distribution of factor V Leiden. Lancet 1995;346:1133-1134
CrossRef | Web of Science | Medline63
Ridker PM ,Miletich JP ,Hennekens CH ,Buring JE . Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 1997;277:1305-1307
CrossRef | Web of Science | Medline64
Rosendaal FR ,Koster T ,Vandenbroucke JP ,Reitsma PH . High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-1508
Web of Science | Medline65
Emmerich J ,Rosendaal FR ,Cattaneo M , et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism -- pooled analysis of 8 case-controlled studies including 2310 cases and 3204 controls. Thromb Haemost 2001;86:809-816[Erratum, Thromb Haemost 2001;86:1598.]
Web of Science | Medline66
Vandenbroucke JP ,Koster T ,Briet E ,Reitsma PH ,Bertina RM ,Rosendaal FR . Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-1457
CrossRef | Web of Science | Medline67
Vandenbroucke JP ,van der Meer FJM ,Helmerhorst FM ,Rosendaal FR . Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996;313:1127-1130
CrossRef | Web of Science | Medline68
Grody WW ,Griffin JH ,Taylor AK ,Korf BR ,Heit JA . American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001;3:139-148
CrossRef | Medline69
Committee on Genetics
CrossRef | Web of Science | Medline70
Nelson RM ,Botkjin JR ,Kodish ED , et al. Ethical issues with genetic testing in pediatrics. Pediatrics 2001;107:1451-1455
CrossRef | Web of Science | Medline71
The American Society of Human Genetics
Web of Science | Medline72
McCabe ERB . Clinical genetics: compassion, access, science, and advocacy. Genet Med 2001;3:426-429
CrossRef | Web of Science | Medline73
Physicians' desk reference. 56th ed. Montvale, N.J.: Medical Economics, 2002.
- Citing Articles (121)
Citing Articles
1
K. Dierickx. 2012. Genetic Screening. , 480-487.
CrossRef2
B. Sarikaya, A. M. McKinney. (2011) Spectrum Bias: Patient Selection May Affect Performance of Calcium Volume in Detecting Carotid Stenosis. American Journal of Neuroradiology
CrossRef3
B. A. Tarini, K. P. Tercyak, B. S. Wilfond. (2011) Commentary: Children and Predictive Genomic Testing: Disease Prevention, Research Protection, and Our Future. Journal of Pediatric Psychology 36:10, 1113-1121
CrossRef4
M. HILL, C. COMPTON, C. LEWIS, H. SKIRTON, L. S. CHITTY. (2011) Determination of foetal sex in pregnancies at risk of haemophilia: a qualitative study exploring the clinical practices and attitudes of health professionals in the United Kingdom. Haemophiliano-no
CrossRef5
W. Burke, B. Tarini, N. A. Press, J. P. Evans. (2011) Genetic Screening. Epidemiologic Reviews 33:1, 148-164
CrossRef6
Rosalie K. Elespuru. (2011) Assessment of heritable genetic effects using new genetic tools and sentinels in an era of personalized medicine. Environmental and Molecular Mutagenesis 52:4, 253-263
CrossRef7
Frauke Becker, Carla G van El, Dolores Ibarreta, Eleni Zika, Stuart Hogarth, Pascal Borry, Anne Cambon-Thomsen, Jean Jacques Cassiman, Gerry Evers-Kiebooms, Shirley Hodgson, A Cécile J W Janssens, Helena Kaariainen, Michael Krawczak, Ulf Kristoffersson, Jan Lubinski, Christine Patch, Victor B Penchaszadeh, Andrew Read, Wolf Rogowski, Jorge Sequeiros, Lisbeth Tranebjaerg, Irene M van Langen, Helen Wallace, Ron Zimmern, Jörg Schmidtke, Martina C Cornel. (2011) Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. European Journal of Human Genetics 19, S6-S44
CrossRef8
Richard R. Sharp. (2011) Downsizing genomic medicine: Approaching the ethical complexity of whole-genome sequencing by starting small. Genetics in Medicine 13:3, 191-194
CrossRef9
Joonas Sirola, Heikki Kröger. (2011) Similarities in Acquired Factors Related to Postmenopausal Osteoporosis and Sarcopenia. Journal of Osteoporosis 2011, 1-14
CrossRef10
David C. Kasper, Rene Ratschmann, Thomas F. Metz, Thomas P. Mechtler, Dorothea Möslinger, Vassiliki Konstantopoulou, Chike B. Item, Arnold Pollak, Kurt R. Herkner. (2010) The National Austrian Newborn Screening Program – Eight years experience with mass spectrometry. Past, present, and future goals. Wiener klinische Wochenschrift 122:21-22, 607-613
CrossRef11
Theresa M Marteau, David P French, Simon J Griffin, A T Prevost, Stephen Sutton, Clare Watkinson, Sophie Attwood, Gareth J Hollands, Theresa M Marteau. 2010. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. .
CrossRef12
Balaji S. Srinivasan, Eric A. Evans, Jason Flannick, A. Scott Patterson, Christopher C. Chang, Tuan Pham, Sharon Young, Amit Kaushal, James Lee, Jessica L. Jacobson, Pasquale Patrizio. (2010) A universal carrier test for the long tail of Mendelian disease. Reproductive BioMedicine Online 21:4, 537-551
CrossRef13
M. Carolina Pardo Silva, Omer T. Njajou, Behrooz Z. Alizadeh, Albert Hofman, Jacqueline C. M. Witteman, Cornelia M. Duijn, A. Cecile J. W. Janssens. (2010) HFE gene mutations increase the risk of coronary heart disease in women. European Journal of Epidemiology 25:9, 643-649
CrossRef14
Sumeet S. Chugh. (2010) Genomics revolution: Forging a path to the arrhythmia patient. Heart Rhythm 7:8, 1149-1150
CrossRef15
Ivana Novaković, Nela Maksimović, Slobodan Cvetković, Dragana Cvetković. (2010) Gene Polymorphisms as Markers of Disease Susceptibility. Journal of Medical Biochemistry 29:3, 135-138
CrossRef16
Melissa K. Hill, Alison D. Archibald, Jonathan Cohen, Sylvia A. Metcalfe. (2010) A systematic review of population screening for fragile X syndrome. Genetics in Medicine 12:7, 396-410
CrossRef17
David Karasik, Douglas P. Kiel. (2010) Evidence for pleiotropic factors in genetics of the musculoskeletal system. Bone 46:5, 1226-1237
CrossRef18
Thomas J. Musci, Krista Moyer. (2010) Prenatal Carrier Testing for Fragile X: Counseling Issues and Challenges. Obstetrics and Gynecology Clinics of North America 37:1, 61-70
CrossRef19
Thomas W. Prior. (2010) Spinal Muscular Atrophy: Newborn and Carrier Screening. Obstetrics and Gynecology Clinics of North America 37:1, 23-36
CrossRef20
Quanhe Yang, W. Dana Flanders, Ramal Moonesinghe, John P.A. Ioannidis, Idris Guessous, Muin J. Khoury. (2009) Using Lifetime Risk Estimates in Personal Genomic Profiles: Estimation of Uncertainty. The American Journal of Human Genetics 85:6, 786-800
CrossRef21
Ephrat Levy-Lahad. (2009) Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: A call for evidence. Genetics in Medicine 11:9, 620-621
CrossRef22
Jill Waalen, Ernest Beutler. (2009) Genetic Screening for Low-Penetrance Variants in Protein-Coding Genes. Annual Review of Genomics and Human Genetics 10:1, 431-450
CrossRef23
Muin J. Khoury, Colleen M. McBride, Sheri D. Schully, John P. A. Ioannidis, W Gregory Feero, A Cecile J. W. Janssens, Marta Gwinn, Denise G. Simons-Morton, Jay M. Bernhardt, Michele Cargill, Stephen J. Chanock, George M. Church, Ralph J. Coates, Francis S. Collins, Robert T. Croyle, Barry R. Davis, Gregory J. Downing, Amy DuRoss, Susan Friedman, Mitchell H. Gail, Geoffrey S. Ginsburg, Robert C. Green, Mark H. Greene, Philip Greenland, Jeffrey R. Gulcher, Andro Hsu, Kathy L. Hudson, Sharon L. R. Kardia, Paul L. Kimmel, Michael S. Lauer, Amy M. Miller, Kenneth Offit, David F. Ransohoff, J Scott Roberts, Rebekah S. Rasooly, Kari Stefansson, Sharon F. Terry, Steven M. Teutsch, Angela Trepanier, Kay L. Wanke, John S. Witte, Jianfeng Xu. (2009) The Scientific Foundation for Personal Genomics: Recommendations from a National Institutes of Health–Centers for Disease Control and Prevention Multidisciplinary Workshop. Genetics in Medicine 11:8, 559-567
CrossRef24
Green, Robert C., Roberts, J. Scott, Cupples, L. Adrienne, Relkin, Norman R., Whitehouse, Peter J., Brown, Tamsen, Eckert, Susan LaRusse, Butson, Melissa, Sadovnick, A. Dessa, Quaid, Kimberly A., Chen, Clara, Cook-Deegan, Robert, Farrer, Lindsay A., . (2009) Disclosure of APOE Genotype for Risk of Alzheimer's Disease. New England Journal of Medicine 361:3, 245-254
Full Text25
Elisabeth Hildt. (2009) Predictive Genetic Testing, Autonomy and Responsibility for Future Health. Medicine Studies 1:2, 143-153
CrossRef26
Linda L. McCabe, Edward R. B. McCabe. (2009) Newborn screening as a system from birth through lifelong care. Genetics in Medicine 11:6, 409-410
CrossRef27
Xiaoming Wang, Lili Liu, James Fackenthal, Shelly Cummings, Oluwatobi I. Olopade, Kisha Hope, Jonathan C. Silverstein, Olufunmilayo I. Olopade. (2009) Translational integrity and continuity: Personalized biomedical data integration. Journal of Biomedical Informatics 42:1, 100-112
CrossRef28
E. M. Maier, S. W. Gersting, K. F. Kemter, J. M. Jank, M. Reindl, D. D. Messing, M. S. Truger, C. P. Sommerhoff, A. C. Muntau. (2009) Protein misfolding is the molecular mechanism underlying MCADD identified in newborn screening. Human Molecular Genetics 18:9, 1612-1623
CrossRef29
G. Marca, S. Malvagia, B. Casetta, E. Pasquini, M. A. Donati, E. Zammarchi. (2008) Progress in expanded newborn screening for metabolic conditions by LC-MS/MS in Tuscany: Update on methods to reduce false tests. Journal of Inherited Metabolic Disease 31:S2, 395-404
CrossRef30
Tzipora C. Falik-Zaccai, Nechama Kfir, Pnina Frenkel, Cindy Cohen, Mary Tanus, Hanna Mandel, Shihab Shihab, Siman Morkos, Salameh Aaref, Marshall L. Summar, Morad Khayat. (2008) Population screening in a Druze community: the challenge and the reward. Genetics in Medicine 10:12, 903-909
CrossRef31
David Karasik. (2008) Osteoporosis: an evolutionary perspective. Human Genetics 124:4, 349-356
CrossRef32
Martin B Delatycki. (2008) Population Screening for Reproductive Risk for Single Gene Disorders in Australia: Now and the Future. Twin Research and Human Genetics 11:4, 422-430
CrossRef33
Theresa M Marteau, David P French, Simon J Griffin, Andrew T Prevost, Stephen R Sutton, Clare Watkinson, Theresa M Marteau. 2008. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. .
CrossRef34
Sylvia Metcalfe, Alice Jacques, Alison Archibald, Trent Burgess, Veronica Collins, Anna Henry, Kathleen McNamee, Leslie Sheffield, Howard Slater, Samantha Wake, Jonathan Cohen. (2008) A model for offering carrier screening for fragile X syndrome to nonpregnant women: results from a pilot study. Genetics in Medicine 10:7, 525-535
CrossRef35
Elizabeth Penziner, Janet K. Williams, Cheryl Erwin, Yvonne Bombard, Anne Wallis, Leigh J. Beglinger, Michael R. Hayden, Jane S. Paulsen. (2008) Perceptions of discrimination among persons who have undergone predictive testing for Huntington's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 147B:3, 320-325
CrossRef36
Sylvia A. Metcalfe, MaryAnne Aitken, Clara L. Gaff. (2008) The Importance of Program Evaluation: How Can it be Applied to Diverse Genetics Education Settings?. Journal of Genetic Counseling 17:2, 170-179
CrossRef37
Wayne D. Hall, Coral E. Gartner, Adrian Carter. (2008) The genetics of nicotine addiction liability: ethical and social policy implications. Addiction 103:3, 350-359
CrossRef38
Linda L. McCabe, Edward R.B. McCabe. (2008) Expanded Newborn Screening: Implications for Genomic Medicine. Annual Review of Medicine 59:1, 163-175
CrossRef39
Claudia Wild. (2008) Polymorphism-screening: genetic testing for predisposition—guidance for technology assessment. Poiesis & Praxis 5:1, 1-14
CrossRef40
Beverly J. Levine, Douglas W. Levine. (2007) How accurately could we screen for individual risk? Using summary data to examine discriminatory accuracy of a risk marker. Preventive Medicine 45:5, 342-347
CrossRef41
Laura Tulloch, Nicholas J Rukin, John Creamer. (2007) Diabetes and a large liver. The Lancet 370:9591, 1006
CrossRef42
Dhavendra Kumar. (2007) Genomic medicine: a new frontier of medicine in the twenty first century. Genomic Medicine 1:1-2, 3-7
CrossRef43
Inmaculada Melo-Martín. (2006) Genetic Testing: The Appropriate Means for a Desired Goal?. Journal of Bioethical Inquiry 3:3, 167-177
CrossRef44
Matthew R.G. Taylor, Janice G. Edwards, Lisa Ku. (2006) Lost in transition: Challenges in the expanding field of adult genetics. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 142C:4, 294-303
CrossRef45
David Seo, Geoffrey S. Ginsburg, Pascal J. Goldschmidt-Clermont. (2006) Gene Expression Analysis of Cardiovascular Diseases. Journal of the American College of Cardiology 48:2, 227-235
CrossRef46
Wolf Rogowski. (2006) Genetic screening by DNA technology: A systematic review of health economic evidence. International Journal of Technology Assessment in Health Care 22:03,
CrossRef47
Clemens B. Tempfer, Lukas A. Hefler, Christian Schneeberger, Johannes C. Huber. (2006) How valid is single nucleotide polymorphism (SNP) diagnosis for the individual risk assessment of breast cancer? / Welchen Stellenwert hat der diagnostische Einsatz von Einzelnukleotid-Polymorphismen (SNPs) bei der individuellen Risikoeinschätzung von Brustkrebs?. LaboratoriumsMedizin 30:3, 160-164
CrossRef48
Alexandra A Gason, Martin B Delatycki, Sylvia A Metcalfe, MaryAnne Aitken. (2006) It's ‘back to school’ for genetic screening. European Journal of Human Genetics 14:4, 384-389
CrossRef49
Steven W.J. Lamberts, Cees H. Langeveld, Jan P. Vandenbroucke. (2006) Population screening for single genes that codetermine common diseases in adulthood had limited effects. Journal of Clinical Epidemiology 59:4, 358-364
CrossRef50
Andreu Segura-Benedicto. (2006) Inducción sanitaria de los cribados: impacto y consecuencias. Aspectos éticos. Gaceta Sanitaria 20, 88-95
CrossRef51
Muin J. Khoury, Kari Jones, Scott D. Grosse. (2006) Quantifying the health benefits of genetic tests: The importance of a population perspective. Genetics in Medicine 8:3, 191-195
CrossRef52
Sabrina Malvagia, Giancarlo la Marca, Bruno Casetta, Serena Gasperini, Elisabetta Pasquini, Maria Alice Donati, Enrico Zammarchi. (2006) Falsely elevated C4-carnitine as expression of glutamate formiminotransferase deficiency in tandem mass spectrometry newborn screening. Journal of Mass Spectrometry 41:2, 263-265
CrossRef53
Cornelia M van Duijn. 2006. Disease Associations: Human Leukocyte Antigen (HLA) and Apolipoprotein E (APOE) Gene. .
CrossRef54
Wolfgang van den Daele. (2006) The Spectre of Coercion: Is Public Health Genetics the Route to Policies of Enforced Disease Prevention?. Community Genetics 9:1, 40-49
CrossRef55
Todd W Rice. (2006) Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa. Vascular Health and Risk Management 2:1, 3-18
CrossRef56
Gloria R Grice, Terry L Seaton, Abigail M Woodland, Howard L McLeod. (2006) Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics 7:1, 61-65
CrossRef57
Donald B. Bailey, Laura M. Beskow, Arlene M. Davis, Debra Skinner. (2006) Changing perspectives on the benefits of newborn screening. Mental Retardation and Developmental Disabilities Research Reviews 12:4, 270-279
CrossRef58
Debra Skinner, Rebecca Schaffer. (2006) Families and Genetic Diagnoses in the Genomic and Internet Age. Infants & Young Children 19:1, 16-24
CrossRef59
Sean A. McGhee, E. Richard Stiehm, Morton Cowan, Paul Krogstad, Edward R.B. McCabe. (2005) Two-tiered universal newborn screening strategy for severe combined immunodeficiency. Molecular Genetics and Metabolism 86:4, 427-430
CrossRef60
D. B. Bailey, D. Skinner, S. F. Warren. (2005) Newborn Screening for Developmental Disabilities: Reframing Presumptive Benefit. American Journal of Public Health 95:11, 1889-1893
CrossRef61
Alexandra A. Gason, Sylvia A. Metcalfe, Martin B. Delatycki, Vicki Petrou, Edith Sheffield, Agnes Bankier, MaryAnne Aitken. (2005) Tay Sachs disease carrier screening in schools: Educational alternatives and cheekbrush sampling. Genetics in Medicine 7:9, 626-632
CrossRef62
George Davey Smith, Shah Ebrahim, Sarah Lewis, Anna L Hansell, Lyle J Palmer, Paul R Burton. (2005) Genetic epidemiology and public health: hope, hype, and future prospects. The Lancet 366:9495, 1484-1498
CrossRef63
Lyle J Palmer, Lon R Cardon. (2005) Shaking the tree: mapping complex disease genes with linkage disequilibrium. The Lancet 366:9492, 1223-1234
CrossRef64
Denis F. Kinane, Hideki Shiba, Thomas C. Hart. (2005) The genetic basis of periodontitis. Periodontology 2000 39:1, 91-117
CrossRef65
Lisa Madlensky, John R. McLaughlin, June C. Carroll, Vivek Goel, John W. Frank. (2005) Risks and benefits of population-based genetic testing for Mendelian subsets of common diseases were examined using the example of colorectal cancer risk. Journal of Clinical Epidemiology 58:9, 934-941
CrossRef66
Emma Warren, Rob Anderson, Ann?? L. Proos, Leslie B. Burnett, Kris Barlow-Stewart, Jane Hall. (2005) Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program. Genetics in Medicine 7:7, 484-494
CrossRef67
Cynthia A. Moore, Muin J. Khoury, Linda A. Bradley. (2005) From Genetics to Genomics: Using Gene-Based Medicine to Prevent Disease and Promote Health in Children. Seminars in Perinatology 29:3, 135-143
CrossRef68
Kathryn A. Phillips, Stephanie L. Van Bebber. (2005) Measuring the value of pharmacogenomics. Nature Reviews Drug Discovery 4:6, 500-509
CrossRef69
Gail Geller, Clair A. Francomano. (2005) Complementary Medicine and Genetic Medicine: Polar Disciplines or Dynamic Partners?. The Journal of Alternative and Complementary Medicine 11:2, 343-347
CrossRef70
Jörg Tost, Ivo Glynne Gut. (2005) Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clinical Biochemistry 38:4, 335-350
CrossRef71
Jeantine Lunshof. (2005) Personalized medicine: how much can we afford? A bioethics perspective. Personalized Medicine 2:1, 43-47
CrossRef72
C. D. Ryff, B. H. Singer. (2005) Social Environments and the Genetics of Aging: Advancing Knowledge of Protective Health Mechanisms. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences 60:Special Issue 1, 12-23
CrossRef73
J. F. Crow, T. E. Johnson. (2005) Comments. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences 60:Special Issue 1, 7-11
CrossRef74
Kee Chan, Jennifer M. Puck. (2005) Development of population-based newborn screening for severe combined immunodeficiency. Journal of Allergy and Clinical Immunology 115:2, 391-398
CrossRef75
Nancy S. Green, Kenneth A. Pass. (2005) Opinion: Neonatal screening by DNA microarray: spots and chips. Nature Reviews Genetics 6:2, 147-151
CrossRef76
A. Butler, S. C. Henderson, R. E. Gordon, A. Dagan, S. Gatt, E. H. Schuchman. (2005) Preimplantation diagnosis of a lysosomal storage disorder by in situ enzymatic activity: ‘Proof of principle’ in acid sphingomyelinase-deficient mice. Journal of Inherited Metabolic Disease 28:1, 1-12
CrossRef77
Kenneth M. Shermock, Thomas R. Gildea, Mendel Singer, James K. Stoller. (2005) Cost-Effectiveness of Population Screening for Alpha-1 Antitrypsin Deficiency: A Decision Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease 2:4, 411-418
CrossRef78
Julian Little, Linda Sharp, Muin J Khoury, Linda Bradley, Marta Gwinn. (2005) The Epidemiologic Approach to Pharmacogenomics. American Journal of PharmacoGenomics 5:1, 1-20
CrossRef79
Thomas J. Musci. (2005) Screening for Single Gene Genetic Disease. Gynecologic and Obstetric Investigation 60:1, 19-26
CrossRef80
José A. Páramo, Ramón Lecumberri, Josune Orbe. (2005) Trombosis arterial y polimorfismos genéticos: demasiados actores, escenario complejo. Medicina Clínica 124:2, 69-74
CrossRef81
Wayne D. Hall. (2005) Will Nicotine Genetics and a Nicotine Vaccine Prevent Cigarette Smoking and Smoking-Related Diseases?. PLoS Medicine 2:9, e266
CrossRef82
Marc D. Schwartz, Beth N. Peshkin, Kenneth P. Tercyak, Kathryn L. Taylor, Heiddis Valdimarsdottir. (2005) Decision Making and Decision Support for Hereditary Breast-Ovarian Cancer Susceptibility.. Health Psychology 24:4, Suppl, S78-S84
CrossRef83
DeWayne M. Pursley, Gary A. Silverman. 2005. Impact of the Human Genome Project on Neonatal Care. , 171-185.
CrossRef84
Ronald J. A. Trent, Bing Yu, Melody Caramins. 2004. Introduction of Molecular Genetics and Genomics Into Clinical Practice. , 676-681.
CrossRef85
Matthew M. Heeney, Nancy C. Andrews. (2004) Iron homeostasis and inherited iron overload disorders: an overview. Hematology/Oncology Clinics of North America 18:6, 1379-1403
CrossRef86
Jeffrey S Wagener, Marci K Sontag, Scott D Sagel, Frank J Accurso. (2004) Update on newborn screening for cystic fibrosis. Current Opinion in Pulmonary Medicine 10:6, 500-504
CrossRef87
Linda O'Reilly, Peter Bross, Thomas J. Corydon, Simon E. Olpin, Jakob Hansen, John M. Kenney, Shawn E. McCandless, Dianne M. Frazier, Vibeke Winter, Niels Gregersen, Paul C Engel, Brage Storstein Andresen. (2004) The Y42H mutation in medium-chain acyl-CoA dehydrogenase, which is prevalent in babies identified by MS/MS-based newborn screening, is temperature sensitive. European Journal of Biochemistry 271:20, 4053-4063
CrossRef88
Wayne D. Hall, Katherine I. Morley, Jayne C. Lucke. (2004) The prediction of disease risk in genomic medicine. EMBO reports 5, S22-S26
CrossRef89
Muin J Khoury. (2004) The case for a global human genome epidemiology initiative. Nature Genetics 36:10, 1027-1028
CrossRef90
Linda L. McCabe, Edward R.B. McCabe. (2004) GENETIC SCREENING: Carriers and Affected Individuals. Annual Review of Genomics and Human Genetics 5:1, 57-69
CrossRef91
SHARON D. HORNER. (2004) Ethics and Genetics. Clinical Nurse Specialist 18:5, 228-231
CrossRef92
Piero Rinaldo, Silvia Tortorelli, Dietrich Matern. (2004) Recent developments and new applications of tandem mass spectrometry in newborn screening. Current Opinion in Pediatrics 16:4, 427-433
CrossRef93
Lukas A. Hefler, Clemens B. Tempfer, Christoph Grimm, Antje Lebrecht, Eva Ulbrich, Georg Heinze, Sepp Leodolter, Christian Schneeberger, Manfred W. Mueller, Axel Muendlein, Heinz Koelbl. (2004) Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 101:2, 264-269
CrossRef94
MAUREEN J. REED, STEPHEN P. KRAFT. (2004) Vision Health Care Providers?? Attitudes and Experiences with Preschool Vision Screening in Ontario. Optometry and Vision Science 81:7, 548-553
CrossRef95
Charles J. Epstein. (2004) Genetic testing: Hope or hype?. Genetics in Medicine 6:4, 165-172
CrossRef96
Robert Listernick, Joel Charrow. (2004) Knowledge without truth: Screening for complications of neurofibromatosis type 1 in childhood. American Journal of Medical Genetics 127A:3, 221-223
CrossRef97
John H Newman, Richard C Trembath, Jane A Morse, Ekkehard Grunig, James E Loyd, Serge Adnot, Fabio Coccolo, Carlo Ventura, John A Phillips, James A Knowles, Bart Janssen, Oliver Eickelberg, Saadia Eddahibi, Phillipe Herve, William C Nichols, Gregory Elliott. (2004) Genetic basis of pulmonary arterial hypertension. Journal of the American College of Cardiology 43:12, S33-S39
CrossRef98
Richard R. Sharp, Michael A. Yudell, Samuel H. Wilson. (2004) Science and society: Shaping science policy in the age of genomics. Nature Reviews Genetics 5:4, 311-315
CrossRef99
Ronald JA Trent, Bing Yu, Melody Caramins. (2004) Challenges for clinical genetic DNA testing. Expert Review of Molecular Diagnostics 4:2, 201-208
CrossRef100
Donald B. Bailey. (2004) Newborn screening for fragile X syndrome. Mental Retardation and Developmental Disabilities Research Reviews 10:1, 3-10
CrossRef101
PENNY L. MIRRETT, DONALD B. BAILEY, JANE E. ROBERTS, DEBORAH D. HATTON. (2004) Developmental Screening and Detection of Developmental Delays in Infants and Toddlers with Fragile X Syndrome. Journal of Developmental & Behavioral Pediatrics 25:1, 21-27
CrossRef102
Christopher P. Austin. (2004) The Impact of the Completed Human Genome Sequence on the Development of Novel Therapeutics for Human Disease*. Annual Review of Medicine 55:1, 1-13
CrossRef103
Jason M Langheier, Ralph Snyderman. (2004) Prospective medicine: the role for genomics in personalized health planning. Pharmacogenomics 5:1, 1-8
CrossRef104
Muin J. Khoury, Quanhe Yang, Marta Gwinn, Julian Little, W. Dana Flanders. (2004) An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genetics in Medicine 6:1, 38-47
CrossRef105
Guttmacher, Alan E., Collins, Francis S., . (2003) Welcome to the Genomic Era. New England Journal of Medicine 349:10, 996-998
Full Text106
Urvashi Bhardwaj, Yao-Hua Zhang, Edward R.B McCabe. (2003) Neonatal hemoglobinopathy screening: molecular genetic technologies. Molecular Genetics and Metabolism 80:1-2, 129-137
CrossRef107
Debra Skinner, Karen L. Sparkman, Donald B. Bailey. (2003) Screening for Fragile X Syndrome: Parent attitudes and perspectives. Genetics in Medicine 5:5, 378-384
CrossRef108
Guttmacher, Alan E., Collins, Francis S., , Clayton, Ellen Wright, . (2003) Ethical, Legal, and Social Implications of Genomic Medicine. New England Journal of Medicine 349:6, 562-569
Full Text109
Muin J. Khoury. (2003) Genetics and genomics in practice: The continuum from genetic disease to genetic information in health and disease. Genetics in Medicine 5:4, 261-268
CrossRef110
Basil Hanss, Leslie A. Bruggeman. (2003) Applications of gene therapy to kidney disease. Current Opinion in Nephrology and Hypertension 12:4, 439-445
CrossRef111
Kathryn A Phillips, David Veenstra, Stephanie Van Bebber, Julie Sakowski. (2003) An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics. Pharmacogenomics 4:3, 231-239
CrossRef112
(2003) Population Screening. New England Journal of Medicine 348:16, 1604-1605
Full Text113
Christine Thompson, Angela Tsiperfal. (2003) Can a 12-Lead ECG Be Used to Assess for Hyperkalemia?. Progress in Cardiovascular Nursing 18:2, 112-113
CrossRef114
(2003) Current Awareness in prenatal diagnosis. Prenatal Diagnosis 23:4, 359-365
CrossRef115
Steven C. Elbein. (2003) The impact of genetic studies of type 2 diabetes on clinical practice. Current Diabetes Reports 3:2, 93-94
CrossRef116
Fred Gilbert. (2003) Criteria for Newborn Screening. Genetic Testing 7:1, 37-38
CrossRef117
Donna J. Drown. (2003) Principles of Population-Based Genetic Screening and Their Importance. Progress in Cardiovascular Nursing 18:2, 113-114
CrossRef118
K.R. MERIKANGAS. (2003) Implications of Genomics for Public Health: The Role of Genetic Epidemiology. Cold Spring Harbor Symposia on Quantitative Biology 68:1, 359-364
CrossRef119
Marco A. Grados, John Walkup, Samuel Walford. (2003) Genetics of obsessive-compulsive disorders: new findings and challenges. Brain and Development 25, S55-S61
CrossRef120
S. L. Ferrari. (2001) Genomics and Osteoporosis: What Are the Implications?. International Bone and Mineral Society Knowledge Environment 1:1, 20040121-0
CrossRef121
E. Seeman. (2001) Clinical and Basic Research Papers: February and March 2003 Selections. International Bone and Mineral Society Knowledge Environment 1:1, 2003089-0
CrossRef
- Letters
